Markets
BSE See NSE See 38,031.13
-305.88 (-0.8%)

Sun Pharma Injects Sporting Chance Of Healthy Returns In The Longs Run

Print

Some of SPIL’s key specialty products are expected to be commercialised in the US in FY19.

To read the entire article, you must be a DSIJ magazine subscriber.

Comments are only visible to subscribers.

DSIJ Mindshare

12345Last